A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

Starting soon · Not applicable

Conditions studied: Effectiveness

In brief

Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need. In May 2025, the targeted B-cell biologic agent Telitacicept was approved for use in adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (GMG) and subsequently initiated in national multicenter clinical trials for adult OMG. Our center published a retrospective study in the Chinese Journal of Evidence-Based Pediatrics in August 2025, which was the first report both domestically and internationally on the efficacy and safety of Telitacicept in four pediatric OMG patients. This study plans to conduct a prospective, multicenter, open-label, single-arm clinical trial aimed at evaluating the effectiveness and safety of Telitacicept in pediatric OMG.

Key facts

Study ID

NCT07298928

Run by

The Children's Hospital of Zhejiang University School of Medicine

People needed

30

Starts

2026-03-10

Expected to finish

2028-12-01

Last updated by the study team

2026-03-06

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient and their legal guardian voluntarily sign the informed consent form.
• Age < 18 years, male or female.
• Diagnosis of OMG according to the Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (2025 Edition).
• Stable administration of any one or combination of the following standard treatments prior to enrollment:
• Cholinesterase inhibitors
• Glucocorticoids

You may not qualify if…

• Active infection under treatment： Patients who are HBsAg positive must be excluded. Patients who are HBsAg negative but HBcAb positive must undergo quantitative HBV-DNA testing. Patients with a positive quantitative HBV-DNA result must be excluded; those with a negative result may be enrolled.
• Severe hepatic or renal insufficiency.
• Patients with malignant tumors other than thymoma.
• Patients within 3 months post-thymectomy.
• Hypogammaglobulinemia (IgG < 400 mg/dL) or IgA deficiency (IgA < 10 mg/dL).
• History of allergy to human-derived biological products.
• Participation in any other clinical trial within 28 days prior to enrollment or within 5 times the half-life of the investigational drug from the previous trial (whichever is longer).
• Patients deemed unsuitable for participation by the investigator (e.g., patients with severe psychiatric disorders).

Where it is running

• Shenzhen children's Hospital of China Medical University — Shenzhen, Guangdong, China
• Children's Hospital Affiliated to Shandong University — Jinan, Shandong, China
• The Children's Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.